SCHEMBL5418743

SCHEMBL5418743

Cc1c(OC2CCC(N3C(=O)c4ccccc4C3=O)CC2)ccc2c1cnn2C1CCCCO1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ RXRA P19793 1/20 0.34
▸ RXRB P28702 1/20 0.34
▸ RXRG P48443 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MAP3K5 Q99683 1/20 0.33
▸ AXL P30530 5/20 0.33
▸ TYRO3 Q06418 5/20 0.33
▸ MERTK Q12866 5/20 0.33
▸ PDE4A P27815 1/20 0.32
▸ PDE4B Q07343 1/20 0.32
▸ PDE4C Q08493 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5418738 1.00 LMNA (0.39) LMNAGAATSHRL3MBTL1RXRA
SCHEMBL5415156 0.84 RXRA (0.36) LMNARXRARXRBRXRGALDH1A1
SCHEMBL5415159 0.84 RXRA (0.36) LMNARXRARXRBRXRGALDH1A1
SCHEMBL5412574 0.83 ALDH1A1 (0.38) LMNAGAARXRARXRBRXRG
SCHEMBL5413157 0.83 ALDH1A1 (0.38) LMNAGAARXRARXRBRXRG
SCHEMBL5412575 0.83 ALDH1A1 (0.38) LMNAGAARXRARXRBRXRG
SCHEMBL5407733 0.83 IRAK4 (0.40) RXRARXRBRXRGAXLTYRO3
SCHEMBL5425470 0.77 CYP4F2 (0.36) LMNAGAARXRARXRBRXRG
SCHEMBL5425473 0.77 CYP4F2 (0.36) LMNAGAARXRARXRBRXRG
SCHEMBL5425465 0.77 CYP4F2 (0.36) LMNAGAARXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 — — US disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 — — US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA LMNA 2226/4885GAA 3382/4885TSHR 2487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback